海外の子宮頸部摘出術のベスト医師 — ページ2

オラサ・ティーラクル医師は産婦人科を専門とし、タイの最高峰の医療機関であるシリラート病院で研修を受けました。

• マヒドン大学シリラート病院医学士
• 同機関の産婦人科専門医資格
• 現在はイントララート病院で診療を行っています

コンボ医師は、MDアンダーソンがんセンターで高度な研修を受けた婦人科腫瘍学の専門医です。子宮がんに対する低侵襲手術を専門としています。

• ESGO認定婦人科腫瘍専門医
• ロボット手術技術の研修修了
• 婦人科がんに関する査読付き論文を多数発表
• 欧州婦人科腫瘍学会会員

ダン・グリサロ教授は婦人科がんの第一人者であり、子宮頸がんおよび標的療法に関する広範な研究を行っています。

• スラスキー医療センター婦人科腫瘍学シニア医師
• スラスキー産婦人科部長
• トロント大学にて婦人科腫瘍学を専門に研修
• 83本の科学論文を執筆
• 複数の国際婦人科腫瘍学会の会員

イントララット病院にて、高度な不妊治療を含む低侵襲婦人科手術を専門としています。

• 腹腔鏡下婦人科手術のトレーニングを受け、認定を取得
• 生殖医療における専門知識と専用の学位を保有
• チェンマイ大学およびシリラート病院を卒業

Dissatat Budhithada医師は、イントララット病院にて婦人科ケアを専門としており、女性の生殖に関する健康に重点を置いています。

• チュラロンコン大学医学部で研修
• ラマティボディ病院の産婦人科ディプロマを保持
• 妊娠、出産、女性の生殖に関する健康の専門家

_doctor_7325_年_の婦人科腫瘍学の専門知識を持つギュヴェン医師は、低侵襲技術を用いた気管切除術を含む複雑な癌手術を行っています。

• トルコ産婦人科学会会員
• 国際的な医学雑誌への論文掲載
• 腹腔鏡およびロボット手術のトレーニング済み
• 妊孕性を温存する癌治療に注力

認定学際的がんセンターの主任医師 – ヴィオラ・フォックス博士は、免疫療法や分子診断を含む包括的な腫瘍治療を専門としています。

• 遺伝学の有資格専門家であり、腫瘍学において14 年の経験を持つ
• ケルン肺疾患クリニックの副主任医師
• がん治療のための分子生物学研究に積極的に取り組んでいる
• ドイツおよびアメリカの腫瘍学会会員

Dediye Dagdevirenは、広範な外科的トレーニングと妊孕性温存への注力を組み合わせ、気管切除術に独自の視点をもたらしています。

• カヌニ・スルタン・スレイマン教育病院の産婦人科専門医
• イスタンブール・アイドゥン大学准教授 – 未来の産婦人科医を育成
• 妊孕性向上を目的とした生殖補助医療の認定資格を保有
• 低侵襲腹腔鏡下手術の技術に精通
• トルコ産婦人科学会会員

Quirónsalud Marbellaの産婦人科部長であるブランコ・エラエス医師は、女性の健康と個別化されたケアに重点を置く多職種チームを率いています。

• 人間味のある出産と低介入の産科ケアを専門とする
• 人間味のある帝王切開プロトコルの導入を推進
• 包括的ながん治療のための多職種乳腺ユニットを開発
• スペイン子宮頸部病理・コルポスコピー学会会員

セヴリーヌ・イボラ医師は、婦人科腫瘍学およびトラケレクトミー（子宮頸部切除術）を含む低侵襲手術を専門としています。ゾーリンゲン市立病院（Städtisches Klinikum Solingen）の主任医師として、包括的な婦人科部門を率いています。

• 婦人科腫瘍学および子宮頸部病理学の認定医
• ロボット支援手術を含む低侵襲技術における豊富な経験
• ドイツの主要な婦人科学会の活動的なメンバー
• 多数の出版物および学会発表の著者

エケン教授は、バフチェシェヒル大学メディカルパーク・ギョズテペ病院のIVFユニットを率いており、複雑な婦人科手術を専門としています。

• 産婦人科で_doctor_10693_年の経験
• 腹腔鏡下子宮摘出術を含む低侵襲手術の専門家
• 子宮虚血/再灌流障害に関する受賞歴のある研究
• 不妊症および婦人科手術に関する30本以上の査読済み論文を発表
• ウスキュダル大学医学部教員

アレムダル医師は、Medical Park Antalya Hospital Complexにてトラケレクトミー（子宮頸部切除術）を専門としており、腫瘍内科における広範なトレーニングを受けています。

• 腫瘍内科の認定医であり、_doctor_9570_年以上の経験を持つ
• トルコの主要な医療機関であるアクデニズ大学で研修
• JCI認定病院であるMedical Park Antalyaに勤務
• 婦人科腫瘍の手術に注力

Kevser Arkan医師（MD）は、チョルルおよびチェルケズキョイにあるOPTIMED Health Groupの婦人科腫瘍外科（産婦人科）のサブスペシャリストです。2026年から同グループに勤務しています。英語とトルコ語で診療を行っています。

臨床的な専門分野は、卵巣がん、子宮内膜がん、子宮頸がんの外科的管理です。根治的子宮全摘出術、センチネルリンパ節マッピングを伴うリンパ節郭清、腫瘍減量術など、複雑な骨盤内手術を行います。vNOTES（傷跡のない腹腔鏡手術）、腹腔鏡手術、開腹手術、子宮鏡手術などの低侵襲手術を提供しています。また、仙骨膣固定術を含む泌尿器婦人科的再建術も行っています。ハイリスク妊娠の管理も行います。

資格：医学博士、ガズィアンテプ大学（2016年）。産婦人科レジデンシー、カフラマンマラシュ・スチュ・イマム大学（2016–2021年）。婦人科腫瘍外科フェローシップ、ディヤルバクル・ガズィ・ヤシャルギル教育研究病院（2022–2025年）。経験：ディヤルバクル母子病院、婦人科腫瘍クリニック（2022–2025年）。アドゥヤマン・カフタ州立病院（2021–2022年）。ギレスン・アルクラTSM（2016年）。

学術活動：2025年には、vNOTESを用いた子宮内膜がん病期分類におけるセンチネルリンパ節マッピングに関する査読付き研究や、vNOTESと腹腔鏡手術の比較結果に関する研究を発表しました。また、骨盤臓器脱と性機能、GTN葉酸レジメン、vNOTES支援による仙骨膣固定術についても報告しています。彼女の論文は、BMC Surgery、Scientific Reports、Journal of Clinical Medicine、Ginekologia Polskaなどのジャーナルに掲載されています。

ロイ・マシアフ医師は、イスラエルのシェバ医療センターの婦人科部長です。低侵襲婦人科手術および妊孕性温存手術を専門としています。マシアフ医師は、AAGLから外科的イノベーションに対するダニエル・F・コット賞を受賞しました。

• イスラエル婦人科内視鏡学会の会長を務める。
• フォーブス誌により、イスラエルのベストドクターに継続的に選出されている。
• 腹腔鏡下子宮摘出術およびロボット支援下筋腫摘出術を専門とする。
• 世界トップ10病院にランクされるシェバ医療センターに勤務。

SERGSから2つのロボットプラットフォームを使用して手術を行う認定を受けた世界初の婦人科医。スタンチウ医師は、ポンデラス・アカデミック病院にて、若年がん患者向けの妊孕性温存手術を専門としています。

• 婦人科腫瘍学およびロボット手術のサブスペシャリスト
• ロイヤル・マーズデン病院およびその他の欧州トップセンターで研修
• 子宮内膜症手術を含む複雑な低侵襲手術を実施
• 主要な国際科学ジャーナルでの論文発表実績あり
• ESGO、BSCCP、IOTA認定を保持

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

キム・テジュン医師は、サムスン医療センターの婦人科腫瘍学を専門としています。

• 広汎子宮頸部切除術（トラケレクトミー）の専門知識を持つ腫瘍婦人科に注力

イ・ジョンウォン医師は婦人科腫瘍学を専門とし、サムスン医療センターで複雑な症例に注力しています。

• 女性生殖器がんの専門知識を持つ婦人科腫瘍医
• 韓国有数のがんセンターに勤務

婦人科腫瘍学の教授であり専門医であるギラッド・ベン・バルーフは、アスタ・メディカルセンターにおけるトラケレクトミー（子宮頸部切除術）の手術において専門的な知見を提供しています。

• 婦人科がんを中心とした婦人科腫瘍学を専門とする
• 主要な医療施設であるアスタ・メディカルセンターに勤務
• トラケレクトミーを必要とする女性に対して専門的なケアを提供